Review and reflection on the development of clinical pharmacy in China
WU Yongpei;YAN Qing;National Institute of Hospital Administration;Pharmacy Administration Commission;Chinese Hospital Association;

..............page:1-8

In vivo study on pharmacokinetics and pharmacodynamics of P167 modified liposomal doxorubicin in rats
TU Yingfeng;LIU Chang;JU Ruijun;XIE Ying;Department of Pharmaceutics;School of Pharmaceutical Sciences;Peking University Healthy Science Center;

..............page:9-14

Simultaneous determination of mycophenolate mofetil and its metabolits in Chinese patients with autoimmune disease by HPLC and method application
CHEN Hongjun;ZHOU Rong;GAN Zhibin;YU Zicheng;ZHANG Yun;TANG Yuanjun;SHEN Jie;Institute of Clinical Pharmacy and Pharmacology;Tongji University School of Medicine;Department of Nephrology;Shanghai Yangpu District Central Hospital;Tongji University School of Medicine;

..............page:14-19

Efficacy and safety of domestic mitiglinide in treatment of type 2 diabetes mellitus
PAN Xiaoyan;SHEN Feixia;LU Xueqin;WU Wenjun;GE Shengjie;GONG Xiaohua;Department of Endocrinology;The First Affiliated Hospital;Wenzhou Medical College;

..............page:20-24

Clinical benefit of maintenance treatment for diffuse large B-cell lymphoma with thalidomide after chemotherapy
YE Huangyang;ZHANG Yinghong;LV Xiaojun;Department of Medical Oncology;The First Affiliated Hospital of Xiamen University;

..............page:24-27

Clinical treatment effect on complicated depressive disorder in elderly coronary heart disease with escitalopram oxalate
LV Xiongsheng;Department of Gerontology;The Secend People ’s Hospital of Lishui;Zhejiang Province;

..............page:28-31

Standardized treatment and pharmaceutical care for metabolic syndrome patients with dyslipidemia
LI Jing;LI Qing;LV Qianzhou;Department of Pharmacology;Zhongshan Hospital;Fudan University;Department of Cardiology;Zhongshan Hospital;Fudan University;

..............page:32-35

Cost-minimization analysis of two chemotherapeutic protocols for advanced nonsmall cell lung cancer
XU Chaojiang;JIANG Yifei;SUN Yi;Department of Pharmacy;The Second Hospital of Jiaxing;Department of Respiratory;The Second Hospital of Jiaxing;Department of Pharmacy;The First Affiliated Hospital;Zhejiang University;

..............page:35-38

Literature analysis of adverse drug reactions of ACEI combining with ARB in the treatment of diabetic nephropathy
HE Xinjun;WANG Siping;Department of Pharmacy;The Third People ’s Hospital of Hangzhou;

..............page:39-45

Outpatient prescriptions sampled analysis of our hospital from 2010 to 2012
JIN Zhiping;LV Qianzhou;Department of Pharmacy;Zhongshan Hospital;Fudan University;

..............page:45-47

lin chuang yao shi can yu xin xue guan nei ke yao wu zhi liao shi jian
zheng guan zuo ;

..............page:48-51

dui yi li 2 xing tang niao bing he bing guan xin bing he xin lv shi chang huan zhe de yong yao fen xi ji yao xue jian hu
yao hui juan ; bo shu hong ; shen yan lin ; li ping ; zhang jian ;

..............page:51-55

lin chuang yao shi zai icu kai zhan yao xue fu wu de dian xing shi li hui gu
wang xiao mei ; jin lie zhou ;

..............page:55-57

jia zhuang xian sui yang ai zhi liao xin yao cabozantinib ping guo suan yan
lv juan li ; liu yang ; sun hui ping ;

..............page:58-62

2014 nian quan guo yi yao xue shu jiao liu hui zuo lin chuang yao xue yu yao xue fu wu yan jiu jin zhan pei xun ban zheng wen tong zhi

..............page:62

cyp450 yang hua huan yuan mei ji yin duo tai xing de lin chuang yan jiu jin zhan
zhang jing jing ; zuo li yan ;

..............page:63-66

zhong guo lin chuang yao xue za zhi tou gao xu zhi

..............page:67-70